Constellation Pharmaceuticals Announces First-Quarter 2019 Financial Results
08 mai 2019 16h15 HE
|
Constellation Pharmaceuticals , Inc.
Company to present an interim update of data from the MANIFEST clinical trial of CPI-0610 at ASCO on June 3 and at EHA on June 15Related investor event at ASCO to be held on June 4 ...
Constellation Pharmaceuticals to Present at the Solebury Trout Class of 2018 Biotech IPOs Investor Day
19 avr. 2019 08h00 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., April 19, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
Constellation Pharmaceuticals Presents Results from Phase 1b Portion of ProSTAR Clinical Trial of CPI-1205 at AACR Meeting
01 avr. 2019 13h00 HE
|
Constellation Pharmaceuticals , Inc.
Clinical activity of CPI-1205 was seen in subsets of advanced metastatic castration-resistant prostate cancer (mCRPC) patientsRecently initiated Phase 2 portion of ProSTAR includes randomized testing...
Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2018 Financial Results
14 mars 2019 17h24 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., March 14, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to...
Constellation Pharmaceuticals to Present at Upcoming Investor Conference
06 mars 2019 14h35 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to...
Constellation Pharmaceuticals Appoints Jessica Christo as Chief Product Development Officer
04 mars 2019 07h00 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to...
Constellation Pharmaceuticals to Present at Upcoming Investor Conferences
22 févr. 2019 13h24 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
Constellation Pharmaceuticals Announces Appointment to Board of Directors
20 févr. 2019 07h00 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...
Constellation Pharmaceuticals Provides Update on MANIFEST Clinical Trial of CPI-0610 in Myelofibrosis, Reviews 2018 Accomplishments, and Announces 2019 Data Disclosure Plans for Lead Programs
03 janv. 2019 07h00 HE
|
Constellation Pharmaceuticals , Inc.
Constellation CEO Jigar Raythatha will present at the J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019, at 4PM PST/7PM ESTThe presentation will include updated results from the first...
Constellation Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
20 déc. 2018 13h34 HE
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover...